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Abstract: Although growth hormone (GH) is primarily associated with linear growth in 
childhood, it continues to have important metabolic functions in adult life. Adult GH deﬁ  ciency 
(AGHD) is a distinct clinical entity, and GH replacement in AGHD can improve body composi-
tion, strength, aerobic capacity, and mood, and may reduce vascular disease risk. While there 
are some hormone-related side effects, the balance of beneﬁ  ts and risks is generally favorable, 
and several countries have approved GH for clinical use in AGHD. GH secretion declines pro-
gressively and markedly with aging, and many age-related changes resemble those of partial 
AGHD. This suggests that replacing GH, or stimulating GH with GH-releasing hormone or a 
GH secretagogue could confer beneﬁ  ts in normal aging similar to those observed in AGHD 
– in particular, could reduce the loss of muscle mass, strength, and exercise capacity leading 
to frailty, thereby prolonging the ability to live independently. However, while most GH stud-
ies have shown body composition effects similar to those in AGHD, functional changes have 
been much less inconsistent, and older adults are more sensitive to GH side effects. Preliminary 
reports of improved cognition are encouraging, but the overall balance of beneﬁ  ts and risks of 
GH supplementation in normal aging remains uncertain.
Keywords: growth hormone, growth hormone-releasing hormone, growth hormone 
secretagogues, aging, sarcopenia, frailty
Introduction
Frailty in the elderly is a syndrome of progressive loss of strength and aerobic capac-
ity that can increase the risk of falls and their complications, and leads in part to this 
functional decline. The result is the need for costly home-based or institutional sup-
port in the rapidly growing part of the population older than 80 years (Merriam et al 
2002, 2003). Sarcopenia, or loss of muscle mass, leads to this progressive functional 
decline. Growth hormone (GH) also declines with age, and the ﬁ  ndings in frail elders 
are similar in many ways to those signs and symptoms found in younger adults with 
GH deﬁ  ciency (AGHD). Replacement of GH or stimulation of GH secretion with GH-
releasing hormone (GHRH) or other GH secretagogues (GHS) would thus seem to be an 
appealing option to delay the onset of frailty in older adults and to prolong the capacity 
for independent living; but the balance of pros and cons is not necessarily the same 
as in AGHD. This review describes the components of the GH axis and their actions, 
compares and contrasts normal aging with AGHD; and summarizes GH replacement 
and the use of GHRH and GHS in these contexts.
Principal components of the growth hormone axis
GH is the most abundant pituitary hormone, accounting for 10% of pituitary dry 
weight (Merriam et al 2002). It plays an important metabolic role in adult life as Clinical Interventions in Aging 2008:3(1) 122
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a partitioning hormone, regulating body composition and 
function (Merriam and Cummings 2003). GH is a 191 amino 
acid protein whose secretion depends on stimulation by the 
hypothalamus and is regulated by tissue responses (Merriam 
et al 2003). There are three hypothalamic factors or peptide 
systems that regulate GH synthesis and secretion (Figure 1): 
somatostatin (SRIF), GHRH, and ghrelin (Anawalt and 
Merriam 2001; Melmed 2006). Somatostatin, a family of 
14 and 28 amino acid peptides, is a potent noncompetitive 
inhibitor of the release of GH and other hormones. It modu-
lates the pituitary GH response to GHRH. GHRH, a 44 amino 
acid peptide, is the principal stimulator of GH synthesis and 
secretion. Ghrelin, discovered in 1999 by Kojima and col-
leagues (Merriam and Cummings 2003), is an endogenous 
ligand for a previously described GHS receptor. While the 
abbreviation GHS technically could be applied to any growth 
hormone secretagogue, it is generally used to refer to ghrelin 
and its mimetics rather than to GHRH. Ghrelin is secreted in 
large quantities by the stomach, and circulates systemically 
at levels high enough to stimulate central GHS receptors, 
with access facilitated by its unique lipophilic octanoyl side 
group, which is also required for binding to the GHS recep-
tor (Merriam 2002). Ghrelin also has appetite-stimulating 
activities distinct from its GH-stimulating effects (Anawalt 
and Merriam 2001).
All of these peptides respond to a variety of stimuli and 
inhibitors, such as sleep, stress, exercise, food intake and 
body composition, and interact to generate the physiologi-
cal pattern of pulsatile GH secretion (Anawalt and Merriam 




























Figure 1 Major components of the GH neuroregulatory system. Question marks on the arrows leading from the stomach indicate uncertainty about the physiological role 
of gastric ghrelin in the regulation of GH; and on arrows from ghrelin in the hypothalamus indicate uncertainty as to whether ghrelin found in the hypothalamus is synthesized 
in neurons there, or is synthesized elsewhere and acts at hypothalamic or pituitary levels. IGF-1 is synthesized in many GH target tissues, but more than 85% of circulating 
IGF-1 is liver-derived. From Anawalt and Merriam 2001.Clinical Interventions in Aging 2008:3(1) 123
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per day, each lasting about 90 minutes and separated by 
120 minutes. Peak GH secretory activity occurs within an 
hour after the onset of deep sleep (Melmed 2006). With 
increasing age, GH pulse amplitude is markedly reduced, and 
there is a loss of the nocturnal GH increase, but the number 
of GH pulses does not change greatly (Ho et al 1987). This 
secretion is modiﬁ  ed by age and sex in addition to the stimuli 
mentioned above (Molitch et al 2006). GH, in turn, stimulates 
the synthesis of insulin-like growth factor-I (IGF-I), which 
mediates many of GH’s effects and is a potent inhibitor of 
GH secretion (Merriam 2002). GH has some direct effects 
as well via GH receptors present on the surface of many 
cell types (Cummings and Merriam 2003). Circulating 
IGF-I is synthesized mainly in the liver, but IGF-I is also 
locally generated in target tissues. The inhibition of IGF-I 
production can create a syndrome of relative GH resistance, 
causing increased GH secretion with decreased GH effects. 
Examples include fasting, malnutrition, and oral estrogen 
therapy (Merriam 2002).
GH promotes lipolysis and inhibits lipogenesis, with a 
resultant redistribution of fat. It inhibits the conversion of 
cortisone to the active glucocorticoid cortisol, accelerates 
the conversion of l-thyroxine to the more biologically active 
triiodothyronine (Cummings and Merriam 2003), and exerts 
antinatriuretic effects by stimulating renal tubular sodium-
potassium pumps and facilitating the renin-angiotensin-
aldosterone system (Merriam and Cummings 2003). 
GH inﬂ  uences bone physiology after linear bone growth 
has ceased, and is anabolic toward bone and muscle. It 
contributes to an increase in overall energy expenditure by 
stimulating protein synthesis and fat oxidation (Cummings 
and Merriam 2003). GH also enhances intestinal absorption 
of calcium and phosphate, vitamin D activity, renal tubular 
phosphate reabsorption, osteoblast proliferation, and synthe-
sis of DNA and procollagen mRNA in bone (Merriam and 
Cummings 2003).
Normal aging vs adult growth 
hormone deﬁ  ciency
GH secretion rates decline exponentially from a peak of 
about 150 µg/Kg/day during puberty to about 25 µg/Kg/day 
by age 55 (Melmed 2006). In this process there is a reduc-
tion in GH pulse amplitude, but little change in GH pulse 
frequency (Merriam et al 2003). There is a particularly 
marked decline in sleep-related GH secretion, resulting 
in loss of the nocturnal pulsatile GH secretion seen in 
younger individuals and lack of a clear night-day GH 
rhythm (Figure 2) (Ho et al 1987; Merriam et al 2000). 
It seems that the age-related decline in GH is not the 
cause of the decline in slow-wave sleep (SWS), however, 
since in most studies administering GH or GHRH does 
not enhance SWS in seniors (Vitiello et al 2001). The 
decline in GH production parallels the age-related decline 
in body mass index and is associated with alterations 
Figure 2 Patterns of GH secretion in younger and older women and men. There is a marked age-related decline in GH secretion in both sexes and a loss of the nighttime 
enhancement of GH secretion seen during deep (slow-wave) sleep. This decrease is primarily due to a reduction in GH pulse amplitude, with little change in pulse frequency. 
L = large GH pulses, S = small GH pulses. From Ho et al 1987.Clinical Interventions in Aging 2008:3(1) 124
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in body composition, hormonal status, and functional capacity 
that mimic the changes seen in AGHD or partial hypogonad-
ism (Merriam et al 1997). In addition to deteriorating memory 
and cognitive function, the changes in body composition that 
are most pronounced in normal aging include a reduction in 
bone density and in muscle mass and strength, an increase in 
body fat, and adverse changes in lipoprotein proﬁ  les (Anawalt 
and Merriam 2001; Merriam and Cummings 2003). While the 
aging pituitary remains responsive to GH, GHRH, and GHS, 
it is less responsive to stimuli such as exercise. This decline in 
GH production is initially clinically silent, but may contribute 
over time to sarcopenia and frailty.
The decline in GH may also play a role in age-associated 
changes in cognition. While there are many systems for clas-
sifying different cognitive domains, often they are grouped 
as “crystallized” vs “ﬂ  uid” intelligence. The former includes 
vocabulary and long-term memory; the latter includes short-
term memory and active problem-solving and declines more 
markedly with aging. A number of studies have shown that 
in older adults there is a signiﬁ  cant correlation between per-
formance on tests of ﬂ  uid intelligence and circulating levels 
of IGF-I (Aleman et al 1999), suggesting that GH may play 
a role in maintenance of ﬂ  uid intelligence.
Several possible mechanisms for the age-related decline 
in GH secretion have been postulated: loss of (or decline 
in) pituitary responsiveness to GHS, increased sensitivity 
to the negative feedback by IGF-I, decline in hypothalamic 
stimulation, and increase in somatostatin inhibition of GH 
(Anawalt and Merriam 2001; Merriam and Cummings 2003). 
Published studies have pointed against the ﬁ  rst two of these 
mechanisms as major factors (Pavlov et al 1996) (Figure 3). 
The precise mix of the latter two factors, and of any others, is 
still not completely understood. Given that the aging pituitary 
can still respond to GHS, that there is no change in sensitiv-
ity to IGF-I, and that there may be some relative deﬁ  ciency 
of GHRH and possibly ghrelin, it seems reasonable to infer 
that the cause of the overall decline of GH secretion with age 
is multifactorial and arises above the level of the pituitary 
(Merriam and Cummings 2003).
Aging is not a disease. Rather, it is a physiological state 
of relative GH deﬁ  ciency. This is demonstrated by higher GH 
secretion and physiological responses seen in older adults 
when compared with AGHD patients of similar age (Merriam 
et al 2002). It is important to distinguish true AGHD from nor-
mal aging, since the consequences of the two states differ.
Since all biochemical tests for GHD are imperfect, 
and their accuracy is strongly affected by the pre-test 
probability of the condition, the most important indicator of 
the likelihood of GHD is the clinical context (Merriam and 
Cummings 2003). Among adults with AGHD, 85% acquire 
the deﬁ  ciency as an adult, mostly from pituitary tumors 
or their treatment with radiation or surgery (Merriam and 
Cummings 2003). Impairment of the hypothalamus may be 
present due to similar processes; although in the presence 
of pituitary damage, which renders them unresponsive to 
GHRH or GHS, this is more difﬁ  cult to gauge. Traumatic 
brain injury is also becoming more frequently recognized 
as a cause of GHD in adults (Merriam and Wyatt 2006; 
Molitch et al 2006), and may produce deﬁ  ciencies in other 
pituitary hormones as well. Studies have shown that adults 
with hypopituitarism have increased mortality compared 
with nonhypopituitary populations adjusted for age and 
sex. The main causes of the excess mortality were cardio-
vascular and cerebrovascular disease (Molitch et al 2006). 
Patients who acquire GHD in adult life also have an increase 
in cardiovascular and cerebrovascular mortality and have 
clinically signiﬁ  cant abnormalities in hormone proﬁ  les, body 
composition, and physical and mental functions (Merriam 
and Cummings 2003).
GHD adults are physically and emotionally less healthy 
than their age-matched peers (Table 1). Their skin is cool, 
dry, and thin. They suffer psychological and social difﬁ  cul-
ties and cognitive impairment. Fat mass is increased by 
7%−10%, with much of the excess located in the visceral 
compartment of the abdomen. Lean body mass is decreased 
by 7%−8% and skeletal muscle volume is diminished by 
up to 15% (Cummings and Merriam 2003; Merriam and 
Cummings 2003). Cardiac muscle is also lost, with impaired 
ventricular function and cardiac capacity as a result. Hyper-
tension is more common, thrombogenic blood components 
are increased, and an atherogenic lipid proﬁ  le exists. All of 
this contributes to the cardiovascular (and cerebrovascular) 
disease seen in AGHD (Merriam et al 2000; Cummings and 
Merriam 2003; Merriam and Cummings 2003; Merriam and 
Wyatt 2006).
Growth hormone replacement
and its side effects
While a single case study in 1962 described improved vigor, 
ambition and well-being in a 35 year old hypopituitary adult 
who received GH, large-scale trials of GH replacement in 
AGHD could not be conducted with scarce extracted pituitary 
GH. With the availability of synthetic GH in unlimited quali-
ties, clinical trials in AGHD were begun soon after recombi-
nant GH was approved for pediatric use in 1985, and results 
of these studies began to appear in the late 1980’s. In 1996 Clinical Interventions in Aging 2008:3(1) 125
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the FDA approved the use of GH in GHD adults (Merriam 
and Cummings 2003; Molitch et al 2006). GH replacement in 
AGHD has been successful in reversing many structural and 
functional abnormalities in the condition (Table 2) (Merriam 
2002; Molitch et al 2006). The beneﬁ  ts and risks of GH 
replacement in AGHD have been documented in more than 
1000 publications (Cummings and Merriam 2003; Merriam 
et al 2003). While dosing was initially derived from pediatric 
practice, doses appropriate for growing children produced 
severe side effects in adults and were rapidly reduced. Over 
time, weight-based dosing as used in pediatrics gave way 
to the current adult practice of beginning with a low ﬁ  xed 
dose unlikely to produce side effects, with subsequent dose 
titration until either an age- and gender-appropriate level of 
IGF-I or side effects are encountered. This titration must 
be conducted particularly carefully in older adults, who are 
more susceptible to adverse effects.
Since aging is a milder GH-deﬁ  cient state than AGHD, 
GH replacement seems a potentially reasonable approach to 
prevention or even reversal of the frailty symptoms of aging. 
The ﬁ  rst studies in non-GHD older adults took place soon 
after its effects in AGHD were published. In a widely cited 
Figure 3 Effects of a single intravenous bolus of GHRH on GH secretion in healthy subjects of different ages. While the highest responses are seen in young adults, there is 
no signiﬁ  cant decrease with aging, and pituitary GH responses are well preserved even in the oldest subjects. From Pavlov et al 1986.Clinical Interventions in Aging 2008:3(1) 126
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study by Rudman et al (1990), healthy men over 60 years old 
responded to 6 months’ GH treatment with an 8.8% increase 
in lean body mass, a 14.4% decrease in adipose tissue mass, 
and a 1.6% increase in vertebral bone mineral density (BMD). 
Since most studies of AGHD have required 12–18 months of 
treatment to show an improvement in BMD, this improve-
ment was especially remarkable. Although the Rudman study 
did not include any functional measures, given these results, it 
was postulated that GH treatment might also improve muscle 
strength and functional performance. Studies of physical 
functional effects, however, have been generally disappoint-
ing and inconsistent. Papadakis et al (1996) tried to determine 
whether GH treatment would improve functional ability in 
older men. The authors concluded that GH supplementation 
improved body composition but not functional status. Since 
the subjects were generally very ﬁ  t and functional scores 
were close to the maximum at the beginning of the trial, it is 
not clear whether this was a true negative result or a “ceiling 
effect” related to the testing measures used.
Despite this lack of demonstrated functional efﬁ  cacy, a 
number of clinics began to offer GH treatment to otherwise 
healthy older men and women. Faced with this growing 
practice and dearth of information, the NIH National Insti-
tute on Aging issued a call for applications in 1991 to study 
trophic factors in aging. Several studies of GH, either alone 
or in combination with sex steroids, IGF-I, or exercise con-
ditioning, and one study of GHRH were funded and have 
now been completed. While a comprehensive review of the 
ﬁ  ndings of these studies is beyond the scope of this article, 
there is a general consensus among these reports that GH 
replacement in normal seniors can elevate levels of IGF-I 
to the young adult normal range. While attempts to repro-
duce the doses used by Rudman and colleagues encountered 
severe side effects, forcing their reduction to 50% or less of 
those he used, target IGF-I levels could usually be reached 
at lower doses with tolerable short-term side effects. There 
is also a general consensus that GH treatment increases 
lean body mass and reduces body fat, especially abdominal 
visceral fat (Blackman et al 2002). The studies that included 
exercise conditioning conﬁ  rmed its beneﬁ  cial effects, but 
GH did not augment exercise effects and there was no clear 
improvement in strength or aerobic capacity with GH alone. 
Studies published to date also provided no deﬁ  nitive proof 
that GH treatment could improve sleep or mood impairment 
(Merriam 2002).
All of these studies were conducted for 6–12 months at 
a single site, and so only short-term intermediate outcomes 
and side effects, not long-term risks, could be observed. Their 
results provide no guidance on the effects of GH on long-term 
clinical outcomes or risks such as falls or fractures, maintenance 
of functional status, or effects on cardiovascular morbidity and 
mortality – factors that would establish more deﬁ  nitively the 
rationale for GH treatment in normal aging (Cummings and 
Merriam 2003; Merriam and Cummings 2003). And while few 
long-term risks have been observed, this reﬂ  ects more a lack 
of information than a demonstration of safety.
Table 1 Clinical features of the adult GHD syndrome
↑ Fat mass (especially abdominal fat)





↓ Bone mineral density
Atherogenic lipid proﬁ  le
Thin, dry skin; poor venous access
Impaired sweating
Psychosocial problems




 Sleep  disturbances
  Emotional lability and impaired self-control
 Social  isolation
  Poor marital and socioeconomic performance
Note: From Merriam and Cummings 2003.
Table 2 Effects of GH replacement in GHD adults
↓ Fat mass (especially abdominal fat)
↑ Lean body mass
↑ Total-body water and plasma volume
↑ Muscle mass strength
↑ Improved cardiac capacity




↑ Resting energy expenditure
↑ Bone mineral density (after 1 yr of treatment)
Altered lipid proﬁ  le
  Decreased total cholesterol
 Decreased  LDL-C
 Decreased  Apo  B
  Decreased triglycerides (if initially elevated)
  Increased HDL-C (not seen in all studies)
 Increased  Lp(a)
↓↑ Insulin sensitivity (↓ acutely, ↑ after changes in body composition)
Common side effects
  Fluid retention; edema
 Arthralgias
  Carpal tunnel syndrome
  Decreased insulin sensitivity (acutely); hyperglycemia
Note: From Merriam and Cummings 2003.Clinical Interventions in Aging 2008:3(1) 127
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Since elders are more sensitive to replacement with GH 
(and GH resistance may not be uniform in all tissues), they are 
also more susceptible to the side effects of therapy. The side 
effects are due to the hormonal effects of over-replacement, 
so careful dose titration is extremely important. Patients 
who are older, heavier, or female are more prone to develop 
complications (Molitch et al 2006). Common side effects 
of GH replacement include ﬂ  uid retention, with peripheral 
edema (40% of patients), arthralgias (20% of patients), and 
carpal tunnel syndrome (10% of patients) (Anawalt and 
Merriam 2001; Cummings and Merriam 2003; Merriam 
and Cummings 2003). Studies have also shown increased 
fasting glucose levels. Although these levels generally return 
toward normal with the improvement in body composition 
and reduced insulin resistance, some studies have found a 
persistent increase in fasting glucose and insulin with chronic 
GH treatment, even after body composition changes have 
stabilized. Other less frequently reported side effects include 
headache, tinnitus, and benign intracranial hypertension 
(Merriam and Cummings 2003; Merriam and Wyatt 2006). 
GH can accelerate both the clearance of thyroxine and 
promote its conversion to triiodothyronine, and so can have 
variable effects in hypothyroid patients on ﬁ  xed replacement 
doses. Since GH and IGF-I are growth factors, there are 
concerns for promotion of cancer cell growth, but studies to 
date have not demonstrated this (Merriam 2002).
Besides these increased vulnerabilities in older patients, 
which are common to the use of GH both in GHD and in 
normal aging, there are concerns speciﬁ  c to the use of GH 
in non-GHD elders. In treatment of GHD, the target for 
dosing is replacement to age-appropriate normal levels. In 
anti-aging therapy, age-appropriate normal levels are the 
starting point, not the target; rather, the target is the normal 
range for young adults, and the balance of beneﬁ  cial effects 
vs adverse effects and risks may thus be quite different in 
these two contexts. The ongoing controversy over the pros 
and cons of postmenopausal estrogen therapy, despite a large 
literature, should raise cautions that only studies conducted 
with the speciﬁ  c dosing targets and in the speciﬁ  c population 
for which the use is being proposed can adequately assess 
those beneﬁ  ts and risks.
Growth hormone-releasing 
hormone and growth hormone 
secretagogues
Growth hormone secretagogues such as GHRH, ghrelin, 
and their mimetics stimulate the secretion of GH, if the 
pituitary is intact and responsive. Since most AGHD is 
due to hypopituitarism, and these patients – unlike normal 
elders – are thus unresponsive to GHRH or GHS, there are 
not many studies of GHS replacement effects, and the use of 
GHS in normal aging has not been approved by regulatory 
authorities in any jurisdiction (Merriam et al 2002, 2003). 
In principle, treatment with GHS should offer a more physi-
ologic approach to GH replacement, leading to a pulsatile 
rather than prolonged elevation in GH and preserving the 
capability for negative feedback inhibition of GH by rising 
levels of IGF-I (Merriam et al 2000; Merriam 2002). GHS 
effects are inﬂ  uenced by the same factors which modulate 
endogenous GHRH secretion, such as negative feedback 
by somatostatin. This normal negative feedback regulation 
offers some buffering against overdose (Merriam et al 2002). 
The side effects of GHRH treatment are similar in character 
to GH treatment, but are milder and less frequent. And, 
since the GHS are smaller molecules than GH, they can be 
administered orally, transdermally, or nasally (Merriam et al 
2003; Merriam and Cummings 2003).
Once daily GHRH injections can stimulate increases 
in GH and IGF-I at least to the lower part of the young 
adult normal range (Merriam et al 2000). The University of 
Washington study of 6 months treatment with daily bedtime 
subcutaneous injections of GHRH(1–29)NH2, alone or in 
combination with supervised exercise conditioning, was 
begun in response to the NIH initiative (Merriam et al 2002, 
2003). IGF-I levels rose approximately 35%. As with GH, 
subjects showed an increase in lean body mass and decrease 
in body fat (particularly abdominal visceral fat). However, 
there was no improvement in strength or aerobic ﬁ  tness 
associated with GHRH injections. Testing again conﬁ  rmed 
the beneﬁ  ts of exercise but showed no effect upon IGF-I 
levels; thus it appears that GH/GHRH and exercise work 
through different mechanisms (Vitiello et al 1997). Subjects 
receiving GHRH also showed no change in scores on an 
integrated physical functional performance test mimicking 
activities of daily living, but there was a signiﬁ  cant decline 
in physical function in the placebo group (Merriam et al 
1997, 2003; Cummings and Merriam 2003). This tantalizing 
ﬁ  nding, suggesting that GHRH can stabilize if not improve 
physical function, needs conﬁ  rmation. There is only one other 
published study of chronic GHRH in normal aging, which 
reported positive effects on exercise testing after 3 months 
of treatment (Veldhuis et al 2005).
Sleep and cognition were also studied in the GHRH trial, 
with surprising results. GHRH failed to improve and may 
even have impaired deep sleep, despite the rise in IGF-I and 
pulsatile GH. However, GHRH treatment was associated Clinical Interventions in Aging 2008:3(1) 128
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with improved scores in several domains of ﬂ  uid (but not 
crystallized) intelligence – those measures previously found 
correlated with circulating IGF-I levels (Vitiello et al 2006). 
This intriguing preliminary ﬁ  nding is now being studied 
more systematically at the University of Washington in a 
new NIH-funded study (the Somatotrophics, Memory, and 
Aging Research Trial, or “SMART”).
Thus as with GH, there is a consensus on hormonal and 
body composition effects but inconsistent functional effects 
on function; and in addition there is a very encouraging but 
still unconﬁ  rmed positive effect on some domains of ﬂ  uid 
intelligence.
Ghrelin, which is produced in the stomach and increases 
during periods of fasting or under conditions associated with 
negative energy balance (such as starvation or anorexia), acts 
at both hypothalamic and pituitary levels via mechanisms 
distinct from GHRH, and thus has different effects from 
GHRH or GH; subjects often gain weight and do not lose, 
or even gain body fat) (Merriam et al 2000, 2002; Liddle 
2006). The effects of ghrelin on GH secretion depend in 
part on the presence of GHRH; and thus if GHRH secretion 
declines with aging, ghrelin’s effects may be blunted. While 
the effects of these two GHS differ clinically, they have syn-
ergistic effects on GH release, and therefore supplementation 
of both substances may be more effective than either alone 
in aging (Merriam et al 2000, 2002). Additionally, there are 
other substances which can enhance GH response to GHS by 
suppressing somatostatin secretion, including arginine and 
beta-adrenergic antagonists, which could potentially enhance 
treatment effects (Merriam et al 1997).
Several studies have shown short-term effects of GHS on 
GH secretion, but so far only three groups have conducted 
studies of their chronic effects in normal aging. Bowers and 
colleagues showed that chronic repeated injections or subcu-
taneous infusions of GH-releasing peptide-2 (GHRP-2) could 
stimulate and maintain increases in episodic GH secretion 
and IGF-I (Bowers et al 2004). Thorner and colleagues at the 
University of Virginia have conducting a study of two years’ 
oral treatment with the non-peptidyl GHS MK-677. As with 
previous studies, there was a sustained increase in IGF-I and 
episodic GH secretion, and an increase in lean body mass 
(Thorner et al 2006). Preliminary functional results over one 
year of treatment, recently reported at an abstract presenta-
tion, however, did not show signiﬁ  cant improvements.
In cooperation with investigators at Duke University 
and several other sites, we conducted a trial of the Pﬁ  zer 
investigational oral GH capromorelin in pre-frail older men 
and women (Merriam et al 2006). This protocol recruited 
over 300 subjects and was initially planned as a two-year 
intervention. The study was unfortunately stopped, how-
ever, after all subjects had been treated for 6 and many for 
12 months, due to failure to see an increase in per cent lean 
body mass, which was a pre-set non-efﬁ  cacy termination 
criterion. Absolute lean body mass did increase signiﬁ  cantly, 
but due to the appetite-stimulating effect of this ghrelin 
mimetic – unforeseen in early 1999 when the study was 
designed and ghrelin was still unknown – subjects also gained 
weight (about 1.5 Kg) and this washed out the effect on per 
cent lean body mass. However, even this truncated study is 
currently the largest clinical trial of chronic GHS treatment 
in aging. It showed the expected increases in IGF-I levels 
and (as noted) total lean body mass. There were also encour-
aging effects on physical functional performance. Of seven 
functional tests, one improved signiﬁ  cantly after 6 months 
of treatment, and another after 12 months. Two other mea-
sures showed non-signiﬁ  cant trends toward improvement, 
and the three remaining measures showed no effect. Effects 
on clinical endpoints such as falls could not be assessed 
with this relatively brief duration of treatment. Side effects 
were generally mild, including increases in fasting blood 
sugar within the normal range. Interestingly, there was a 
self-reported deterioration of sleep quality, though formal 
sleep testing was not performed. Cognition was not studied 
in this trial.
Thus as with GH and GHRH, reports of the hormonal 
and body composition effects of ghrelin mimetic GHS in 
normal aging are relatively consistent, but there is no con-
sensus on functional effects among these very few studies, 
and of course none could assess clinical ﬁ  nal outcomes or 
long-term risks.
Conclusion
Sarcopenia and subsequent frailty lead to loss of indepen-
dence. While aging is not a disease, it results in signiﬁ  cant 
body composition and functional changes which affect the 
individual and the community at large. Aging represents a 
milder form of adult GHD, and GH replacement in GHD 
has met with success. Since the aging pituitary remains 
responsive to GH and GHS, it is reasonable to suggest that 
GH replacement or stimulation might be indicated in aging. 
However, elders are more sensitive to GH, and thus more 
susceptible to the side effects of replacement. Stimulating 
GH with GHS instead of GH replacement has the advantage 
of a more physiological approach to increase endogenous GH 
pulsatility with theoretically decreased risk for side effects 
(Arvat et al 2000).Clinical Interventions in Aging 2008:3(1) 129
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Reports of stabilization or even improvement of physical 
function with GHRH or with oral GHS are extremely tan-
talizing, but they are hardly proof that Ponce de Leon’s 
“Fountain of Youth” has been found. The failure to replicate 
these ﬁ  ndings consistently across studies reminds us of the 
origins of the word “tantalizing.” In mythology, Tantalus, 
chained to a rock, bent down to drink from the pool of water 
around him – and the water receded just out of reach. So far, 
deﬁ  nitive conclusions regarding functional effects of GHRH 
and GHS in normal aging have also been out of our reach; 
and until we know whether the age-related decline in GH 
secretion is pathological or adaptive, and until more studies 
are undertaken to study this and the long term effects of GH 
and GHS supplementation, conclusive statements about the 
beneﬁ  ts of treatment cannot be made and we can only rec-
ommend their use in well-controlled clinical studies. Long 
term studies on hard clinical endpoints, such as decreased 
fractures and falls, increased function and quality of life, and 
decreased morbidity and mortality from vascular disease need 
to be performed in order to establish the role, if any, for GH 
and GHS treatment in normal aging.
Note
Presented in part at the Second Annual Meeting of the Society 
for Applied Research in Aging (SARA), 11 November 2006.
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